GlassScriptPhysician profile
Ramarao Pasupuleti
NPI 1548235674
$2,854.96
in general payments reported to CMS, 2019-2025
28 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $130 · 2021: $552 · 2022: $807 · 2023: $475 · 2024: $267 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.19 | 2021-2025 | |
| Amgen INC. | $309.69 | 2019-2023 | Aimovig |
| Pfizer INC. | $208.15 | 2019-2025 | |
| Lilly USA, LLC | $186.47 | 2019-2022 | |
| Stimwave Technologies Incorporated | $177.28 | 2019-2022 | |
| Abbott Laboratories | $161.77 | 2023 | Proclaim |
| Grt US Holding, INC. | $154.00 | 2022 | |
| Mml US, INC. | $125.07 | 2023 | Reactiv8 |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceuticals, INC. | $89.05 | 2021 | |
| Collegium Pharmaceutical, INC. | $86.06 | 2022-2024 | Belbuca, Xtampza |
| Teva Pharmaceuticals USA, INC. | $83.09 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.60 | 2022 | |
| Lundbeck LLC | $63.14 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $58.08 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $56.79 | 2024 | Tymlos |
| Vertex Pharmaceuticals Incorporated | $53.02 | 2024-2025 | |
| Si-Bone, INC. | $52.23 | 2020-2025 | |
| Saluda Medical Americas, INC. | $37.42 | 2025 | Evoke |
| Nevro Corp. | $31.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $24.43 | 2019 | |
| Nalu Medical, INC. | $22.38 | 2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Assertio Therapeutics, INC. | $16.47 | 2020 | |
| Tonix Medicines, INC. | $16.23 | 2025 | Tonmya |
| Almatica Pharma LLC | $15.88 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.16 | 2024 | Horizant |
| Mdd US Operations, LLC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramarao Pasupuleti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.